Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
April 27, 2021 11:39 ET | Sorrento Therapeutics, Inc.
STI-3031 was discovered from Sorrento’s fully human G-MAB™ library.Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications.These...